Discovery of novel L-type voltage-gated calcium channel blockers and application for the prevention of inflammation and angiogenesis
Open Access
- 25 April 2020
- journal article
- research article
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 17 (1) , 1-23
Abstract
Background: The ways in which microglia activate and promote neovascularization (NV) are not fully understood. Recent in vivo evidence supports the theory that calcium is required for the transition of microglia from a surveillance state to an active one. The objectives of this study were to discover novel L-type voltage-gated channel (L-VGCC) blockers and investigate their application for the prevention of inflammation and angiogenesis.Methods: Pharmacophore-based computational modeling methods were used to screen for novel calcium channel blockers (CCBs) from the ZINC compound library. The effects of CCBs on calcium blockade, microglial pro-inflammatory activation, and cell toxicity were validated in BV-2 microglial cell and freshly isolated smooth muscle cell (SMC) cultures. Laser-induced choroidal neovascularization (NV) and the suture-induced inflammatory corneal NV models of angiogenesis were used for in vivo validation of the novel CCBs. CX3CR1gfp/+mice were used to examine the infiltration of GFP-labeled microglial cells.Results: We identified three compounds from the ZINC database (Zinc20267861, Zinc18204217, and Zinc33254827) as new blockers of L-type voltage-gated calcium channels (L-VGCC) using a structure-based pharmacophore approach. The effects of the three CCBs on Ca2+influx into cells were verified in BV-2 microglial cells using Fura-2 fluorescent dye and in freshly isolated SMCs using the voltage-patch clamp. All three CCBs reduced microglial cell migration, activation stimulated by lipopolysaccharide (LPS), and reduced the expression of the inflammatory markers NF-κB (phospho-IκBα) and cyclooxygenase-2 (COX-2) as well as reactive oxygen species. Of the three compounds, we further examined the in vivo activity of Zinc20267861. Topical treatment with Zinc20267861 in a rat model of suture-induced inflammatory cornea neovascularization demonstrated efficacy of the compound in reducing monocyte infiltration and overall corneal NV response. Subconjunctival administration of the compound in the choroidal NV mouse model effectively prevented CNV and microglial infiltration.Conclusions: Our findings suggest that the novel CCBs identified here are effective anti-inflammatory agents that can be further evaluated for treating NV disorders and can be potentially applied in the treatment of ocular inflammatory and pathological angiogenetic disorders.Keywords
Funding Information
- NIH (EY027824)
- Missouri University (Start-up)
- Linköping University (Ogonfonden Award)
This publication has 65 references indexed in Scilit:
- Time-dependent LXR/RXR pathway modulation characterizes capillary remodeling in inflammatory corneal neovascularizationAngiogenesis, 2018
- Novel 1, 4-dihydropyridines for L-type calcium channel as antagonists for cadmium toxicityScientific Reports, 2017
- Microglia in Physiology and DiseaseAnnual Review of Physiology, 2017
- A microarray whole-genome gene expression dataset in a rat model of inflammatory corneal angiogenesisScientific Data, 2016
- Calcineurin and glial signaling: neuroinflammation and beyondJournal of Neuroinflammation, 2014
- The NF-κB Signaling Protein Bcl10 Regulates Actin Dynamics by Controlling AP1 and OCRL-Bearing VesiclesDevelopmental Cell, 2012
- Toward in silico structure-based ADMET prediction in drug discoveryDrug Discovery Today, 2012
- Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activationNeuropharmacology, 2009
- Purinergic signaling and microgliaPflügers Archiv - European Journal of Physiology, 2006
- Role of microglia in multiple sclerosisCurrent Neurology and Neuroscience Reports, 2005